Recently a report examining the methylation of CDH13, CDKN2A/p16, FHIT, RARB, RASSF1A and ZMYND10 (BLU) in which methylation of any 2 loci in plasma was considered cancer positive showed 73% sensitivity and 82% specificity [45]. Here, CDH13 is linked to cancer.